Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.

Müller N, Schwarz MJ.

Mol Psychiatry. 2007 Nov;12(11):988-1000. Epub 2007 Apr 24. Review.

PMID:
17457312
2.

[Immunological aspects of depressive disorders].

Müller N, Schwarz MJ.

Nervenarzt. 2007 Nov;78(11):1261-73. Review. German.

PMID:
17928982
3.

Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Muller N, Schwarz M.

Neurotox Res. 2006 Oct;10(2):131-48. Review.

PMID:
17062375
4.

COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.

Müller N.

Curr Opin Investig Drugs. 2010 Jan;11(1):31-42. Review.

PMID:
20047157
5.

COX-2 inhibition in schizophrenia and major depression.

Müller N, Schwarz MJ.

Curr Pharm Des. 2008;14(14):1452-65. Review.

PMID:
18537668
6.

Cytokines and major depression.

Schiepers OJ, Wichers MC, Maes M.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17. Epub 2005 Jan 25. Review. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2005 May;29(4):637-8.

PMID:
15694227
7.

The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression.

Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):702-21. doi: 10.1016/j.pnpbp.2010.12.017. Epub 2010 Dec 23. Review.

PMID:
21185346
8.

The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.

Miüller N, Schwarz MJ.

J Neural Transm Suppl. 2007;(72):269-80. Review.

PMID:
17982903
9.

A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression.

Miura H, Ozaki N, Sawada M, Isobe K, Ohta T, Nagatsu T.

Stress. 2008 May;11(3):198-209. doi: 10.1080/10253890701754068. Review.

PMID:
18465467
10.

Inflammatory biomarkers and depression.

Müller N, Myint AM, Schwarz MJ.

Neurotox Res. 2011 Feb;19(2):308-18. doi: 10.1007/s12640-010-9210-2. Epub 2010 Jul 24. Review.

PMID:
20658274
11.

The HPA and immune axes in stress: the involvement of the serotonergic system.

Leonard BE.

Eur Psychiatry. 2005 Oct;20 Suppl 3:S302-6. Review.

PMID:
16459240
12.
13.

[New developments on the serotonin hypothesis of depression: shunt of tryptophan].

Marazziti D, Baroni S, Picchetti M, Piccinni A, Silvestri S, Dell'Osso L.

Riv Psichiatr. 2013 Jan-Feb;48(1):23-34. doi: 10.1708/1228.13612. Review. Italian.

PMID:
23438698
14.

The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.

Wichers MC, Maes M.

J Psychiatry Neurosci. 2004 Jan;29(1):11-7.

PMID:
14719046
16.

Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.

Saito K, Markey SP, Heyes MP.

Neuroscience. 1992 Nov;51(1):25-39.

PMID:
1465184
17.

Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.

Myint AM, Kim YK.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:304-13. doi: 10.1016/j.pnpbp.2013.08.008. Epub 2013 Oct 31. Review.

PMID:
24184687
18.

Chronic immune activation underlies morbid obesity: is IDO a key player?

Brandacher G, Hoeller E, Fuchs D, Weiss HG.

Curr Drug Metab. 2007 Apr;8(3):289-95. Review.

PMID:
17430117
19.

Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.

Müller N, Myint AM, Schwarz MJ.

Curr Pharm Des. 2011;17(2):130-6. Review.

PMID:
21361867
20.

Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression.

Myint AM, Kim YK.

Med Hypotheses. 2003 Nov-Dec;61(5-6):519-25.

PMID:
14592780

Supplemental Content

Support Center